Pomegranate extract supplement shows potential in improving glycemic indicators, serum lipids, anthropometrics, and blood pressure in patients with nonalcoholic fatty liver disease.
Randomised Controlled Trial Blood Sugar Cholesterol Diastolic Blood Pressure
The study involved 44 patients who had been diagnosed with nonalcoholic fatty liver disease. These individuals were randomly assigned to two groups, with one group receiving two pomegranate extract tablets daily over a period of 12 weeks, and the other a placebo. The researchers measured anthropometric values, serum lipid levels, blood pressure, and glycemic indicators before and after the intervention.
In their analysis of the outcomes, the researchers found that the group which received the pomegranate extract showed reductions in total cholesterol, triglyceride levels, the ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol, fasting blood sugar, resistance to insulin, diastolic blood pressure, weight, body mass index, and waist circumference when compared to the placebo group. Additionally, an increase in serum high-density lipoprotein cholesterol was observed within the pomegranate group, indicating the potential utility of this supplement in a treatment regimen for this condition.
View Article